



| Align Summit

October 15, 2026

Sheraton Boston Hotel

#AlignSummit26 #PatientDriven

About MassBio

MassBio is the driving force behind Massachusetts's life sciences ecosystem, supporting innovation and industry growth by offering best-in-class resources to over 1,700 member organizations at all stages of the biopharma lifecycle. Founded in 1985, MassBio aspires to extend Massachusetts's impact as the global center of excellence in biomedical breakthroughs.

Upcoming Events

**R&D Reimagined –
Techbio Solutions**
November 2

Patient Advocacy Summit
November 12

State of Possible Conference
April 8, 2027



Learn More
massbio.org/events

Sponsor an Event

Every year, MassBio hosts an abundance of events that come with sponsorship opportunities to help you access and engage with the leading life sciences cluster in the world.



Learn More
massbio.org/sponsor



Welcome



Dear Friends,

Welcome to the 2026 MassBio Align Summit.

Massachusetts companies closed 101 venture rounds in the first half of this year, up from 93 a year ago, and the average round here was \$34.1 million against a national average of \$21.4 million. The recovery is real. It is also uneven. The average seed round fell from \$7.65 million to \$4.65 million, and the ten largest deals took nearly half of every venture dollar that came into the state. New companies are starting here with smaller checks behind them.

That gap is why the Align Summit exists.

Throughout today more than 50 companies will present across five tracks, from advanced biologics to next-generation genetic technologies. Several came through MassBio's Drive accelerator, where we work with founders at exactly the stage where the money is thinnest. You will see the merging of biology and computation up close in the AI for drug discovery track, where the science on stage would have been a decade of work not long ago. You will meet founders one-on-one in partnering meetings, and you will hear pharma business development leaders say plainly what they are looking for and why.

You will also hear from regulators, current and former. A deputy director of policy at the Securities and Exchange Commission and a former senior FDA official share a stage today, one on how companies raise money and the other on the path from first-in-human trials to approval. Every company presenting today is being valued on assumptions about both.

Massachusetts remains the center of gravity for biomedical innovation, and holding that position is no longer a matter of running our own race. The competition is global, well capitalized, and moving quickly. Our advantage has always been density, the odds that the right two people end up in the same room.

So use the room. Sit in on a track outside your thesis. Take the meeting with a company a stage earlier than you would normally look. No one in this room funds a company alone. The handoffs between us are where good science tends to stall.

Thank you for being part of this year's Summit, and for the work you do to get medicines to the patients waiting on them.

With gratitude,

A stylized, handwritten signature in black ink, appearing to read 'KB'.

Kendalle Burlin O'Connell
CEO & President, MassBio

Agenda

8:00 AM – 9:00 AM **Registration**

9:00 AM – 9:15 AM **Welcome & Opening Remarks**

Jason Cordeiro, Chief Operating & Innovation Officer | MassBio

Kendalle Burlin O'Connell, CEO & President | MassBio

9:15 AM – 9:45 AM **Panel - 2027 Pharma Lookahead:
What Buyers Want from Innovation, Partnerships, and M&A**

Vivek Arora, Senior Partner | McKinsey & Company

Irene Blat, Head of External Innovation, North America | Servier

Liz Leveille, VP, BD&L and Head, Boston Innovation Hub & Discovery Transactions | Merck

Jim MacKrell, Vice President | Lilly Ventures Science Teams

Pitch Track Agenda

9:45 AM – 4:00 PM **Advanced Biologics & Protein Therapeutics** | Constitution A

9:45 AM – 4:00 PM **AI for Drug Discovery & Development** | Back Bay A

9:45 AM – 4:00 PM **Diagnostics & Biomarkers** | Independence East

9:45 AM – 4:00 PM **Engineered Molecular Medicines** | Independence West

9:45 AM – 4:00 PM **Next-Generation Genetic Technologies** | Constitution B

12:20 PM – 12:30 PM **Lunch Welcome**

Jason Cordeiro, Chief Operating & Innovation Officer | MassBio

12:30 PM – 12:50 PM **Briefing - Washington and Your Portfolio: A Policy Outlook for Funders**

John Stanford, Partner & CEO | Novel Strategies

12:50 PM – 1:20 PM **Panel - Regulators on the Record:
What's Shifting Across Capital, Approval, and Research**

Errik Anderson, CEO & Founder | Alloy Therapeutics

Hilary Marston, Principal, Clinical and Regulatory Strategy | Canal Row Advisors

Jenny Riegel, Deputy Director, Policy | U.S. Securities and Exchange Commission

John Stanford, Partner & CEO | Novel Strategies

2:40 PM – 3:00 PM **Networking Break**

4:00 PM – 6:00 PM **Reception**

Notice of Photography: Photography and videography will be taking place at this event. Images and videos may be used for promotional purposes. If you do not wish to be photographed or filmed, please inform a staff member.

(as of 9/16/26)

Pitch Track Agenda

Advanced Biologics & Protein Therapeutics Track

LOCATION:
CONSTITUTION A

10:00 AM – 10:20 AM	PathCision Medicine
10:20 AM – 10:40 AM	Overture Therapeutics
10:40 AM – 11:00 AM	Hiba Therapeutics
11:00 AM – 11:20 AM	Othelium Therapeutics
11:20 AM – 11:40 AM	IMMEDIATE Therapeutics
1:40 PM – 2:00 PM	Consano Bio
2:00 PM – 2:20 PM	Laurel Biotherapeutics
2:20 PM – 2:40 PM	Calluna Pharma
3:00 PM – 3:20 PM	KAHR Bio
3:20 PM – 3:40 PM	Harmonia Therapeutics
3:40 PM – 4:00 PM	Valink Therapeutics

AI for Drug Discovery & Development Track

LOCATION:
BACK BAY A

10:00 AM – 10:20 AM	Neoclease
10:20 AM – 10:40 AM	Absentia Labs
10:40 AM – 11:00 AM	QurieGen
11:00 AM – 11:20 AM	Unravel Biosciences
11:20 AM – 11:40 AM	Marendis Therapeutics
1:40 PM – 2:00 PM	GUSKA
2:00 PM – 2:20 PM	AMPLY Discovery
2:20 PM – 2:40 PM	Profluent Bio
3:00 PM – 3:20 PM	ScriptBio AI
3:20 PM – 3:40 PM	Switchback Therapeutics
3:40 PM – 4:00 PM	Coastline Biomedicine

(as of 9/16/26)

Pitch Track Agenda

Diagnostics & Biomarkers Track

LOCATION:
INDEPENDENCE EAST

10:00 AM – 10:20 AM	Delve Bio
10:20 AM – 10:40 AM	Dxcover
10:40 AM – 11:00 AM	Cellens
11:00 AM – 11:20 AM	NeuroSkye Therapeutics
11:20 AM – 11:40 AM	AGED Diagnostics
1:40 PM – 2:00 PM	CellsBin
2:00 PM – 2:20 PM	Nanopath
2:20 PM – 2:40 PM	Nine Diagnostics
3:00 PM – 3:20 PM	Diag-Nose.io
3:20 PM – 3:40 PM	General Prognostics
3:40 PM – 4:00 PM	PolygenRx

Engineered Molecular Medicines Track

LOCATION:
INDEPENDENCE WEST

10:00 AM – 10:20 AM	Rapafusyn
10:20 AM – 10:40 AM	Relevium Medical
10:40 AM – 11:00 AM	Skeletalis
11:00 AM – 11:20 AM	Unison Medicines
11:20 AM – 11:40 AM	Promakhos Therapeutics
1:40 PM – 2:00 PM	BDUK Therapeutics
2:00 PM – 2:20 PM	General Oncology
2:20 PM – 2:40 PM	SignaCor
3:00 PM – 3:20 PM	Iluminos Therapeutics
3:20 PM – 3:40 PM	MelliCell
3:40 PM – 4:00 PM	Noa Therapeutics

(as of 9/16/26)

Pitch Track Agenda

Next-Gen Genetic Technologies Track

LOCATION:
CONSTITUTION B

10:00 AM – 10:20 AM	Armatus Bio
10:20 AM – 10:40 AM	RNA NanoBiotics
10:40 AM – 11:00 AM	Tinker Therapeutics
11:00 AM – 11:20 AM	Tevard Biosciences
11:20 AM – 11:40 AM	Syndeo Life
1:40 PM – 2:00 PM	Gensaic
2:00 PM – 2:20 PM	Amaryllis Therapeutics
2:20 PM – 2:40 PM	Theripio Innovations
3:00 PM – 3:20 PM	i-RNA Corporation
3:20 PM – 3:40 PM	FluidForm Bio
3:40 PM – 4:00 PM	GT Biosciences

(as of 9/16/26)

Speakers



Errik Anderson

CEO & Founder | Alloy Therapeutics

Errik B. Anderson is the CEO and Founder of Alloy Therapeutics, a Product Development Organization (PDO) supporting partners in the discovery, development and commercialization of their

therapeutic drug programs. He started his career at Lehman Brothers Venture Capital and continues his venture work as the GP at 82VS, Alloy's affiliated venture studio, and as the CEO of his single-family office, Ulysses Diversified Holdings. Errik has been the founder or co-founder of a number of successful private and public biotech companies including Alloy, Adimab, Compass Therapeutics, Alector, Avitide and Arsanis. Errik's companies are responsible for discovering over 115 therapeutic antibodies currently under review or approved by the FDA. Errik received his A.B. from Dartmouth, an M.B.A. from The Tuck School of Business and studied bioengineering at The Thayer School of Engineering. He is the co-founder and owner of the three-time National Champion New England Free Jacks, part of Major League Rugby. Errik is on a number of non-profit and for-profit boards, including the Tuck School of Business at Dartmouth.



Vivek Arora

Senior Partner | McKinsey & Company

Vivek Arora is a Senior Partner at McKinsey & Company and a leader in the firm's Life Sciences Practice. Based in Boston, he advises biopharma and biotechnology companies on growth, innovation,

and value creation. His work spans the life sciences ecosystem, helping leaders maximize value from external innovation, strategic partnerships, and transactions. Vivek has also advised on M&A and integration efforts across several advanced modalities, including biologics, cell and gene therapies, and radiopharmaceuticals. Through his work with innovators, investors, and pharmaceutical leaders, he brings a unique perspective on the trends shaping partnerships, dealmaking, and innovation across the life sciences industry.



Irene Blat

Head of External Innovation, North America | Servier

Irene Blat is an oncology leader specializing in scientific evaluation and strategic partnerships. She is currently Head of External Innovation, North America at Servier, where she partners

with VCs, incubators, accelerators and early-stage biotech to source novel therapeutics and platform technologies to in-license for the oncology and neurology pipelines. Irene's leadership over the last 11 years spans roles at Servier, Veracyte, and Genuity Science, where she supported strategic collaborations in oncology precision medicine and AI-driven target discovery. Prior to her transition to industry, Irene started her career as a researcher having trained at the Broad Institute and Massachusetts General Hospital. She holds a Ph.D. in Genetics from MIT, and earned a B.S. in Biology from Duke University.



Jason Cordeiro

Chief Operating & Innovation Officer | MassBio

Jason is the Chief Operating & Innovation Officer. He joined MassBio in September of 2018 as the Vice President of Consortium Operations. In his role, Jason is responsible for managing business

services for our members including; all Edge purchasing and rewards programs, supporting partnering initiatives, sponsor visibility and branding, and MassBioHub sales.

Jason received a B.S. in Biology from Emmanuel College. He had worked at BIDMC researching the effects of NSAIDS on ovarian, prostate, and breast cancers and had spent nine years with Thermo Fisher Scientific in various commercial roles. He currently resides on the South Shore with his wife and two children.

Speakers



Liz Leveille

VP, BD&L and Head, Boston Innovation Hub & Discovery Transactions | Merck

Liz brings over 25 years industry experience and over the past 20 years has focused her work on business development at large pharmaceutical companies.

She has been with Merck for over twelve years and is currently the Head of the Merck Boston Innovation Hub and the Discovery Transactions team which are Business Development & Licensing teams focused on early-stage therapeutics (prior to human proof-of-concept) as well as accessing innovative research and technologies through collaboration, licensing, or M&A in the academic, pharma, and biotech community. During her time at Merck, in addition to leading her team through multiple important deals, she has led transactions including the acquisition of Themis Bioscience and the collaboration with Astex and Taiho Pharmaceuticals, among others.

Previous to Merck, she spent nine years at the Novartis Institutes for BioMedical Research (NIBR) on the business development team.

Liz also has industry experience in scientific roles, given her time at companies such as AVEO Pharmaceuticals, Akceli, Millennium, and Genzyme. Liz has Bachelor and Master of Science degrees in biotechnology from Worcester Polytechnic Institute and a Master of Business Administration from the F.W. Olin Graduate School of Business at Babson College.



Jim MacKrell

Vice President | Lilly Ventures Science Teams

Jim MacKrell, PhD, is Vice President and the Global Head of Lilly Ventures Science Teams. He is responsible for providing scientific leadership for Lilly's venture capital strategy, including implementation

of Lilly's early phase external innovation and Catalyze360 partnering initiatives. He leads teams across San Francisco, Boston, Europe and the APAC region, with the goal of expanding Lilly's scientific reach within the VC and biotech network globally. Jim and his team work across the innovation ecosystem to identify investment and partnership opportunities. He has helped lead multiple investments in biotech and VC firms on behalf of Lilly

Ventures which have resulted in pipeline impact for Lilly and/or positive returns for Lilly Ventures. He serves as a board member for several portfolio companies including Mediar Tx and Superluminal Medicines.

Jim holds a degree in biology and biomedical engineering from Carnegie Mellon University and a doctorate in Molecular Physiology from the University of Michigan Medical School.



Hilary Marston

Principal, Clinical and Regulatory Strategy | Canal Row Advisors

Dr. Marston was FDA's inaugural Chief Medical Officer, serving as the primary clinical advisor to the Commissioner and leading the office that oversees clinical matters

involving multiple FDA product development centers, including financial incentives (e.g., for rare disease product development), targeted grantmaking, and research participant protection policy. She also led the Agency's response to health crises, including epidemics and medical product shortages.

Dr. Marston previously served as Senior Advisor for Global COVID-19 Response on the White House COVID-19 Response Team, as Director for Medical Biopreparedness and Response at the U.S. National Security Council, and as Policy Advisor for Pandemic Preparedness at the National Institute of Allergy and Infectious Diseases. She also worked at McKinsey & Company and the Bill & Melinda Gates Foundation.

Dr. Marston trained in Internal Medicine and Global Health Equity at Brigham & Women's Hospital. She completed her M.P.H. at the Harvard School of Public Health.

Speakers



Kendalle Burlin O'Connell

CEO & President | MassBio

Kendalle Burlin O'Connell is a seasoned and effective executive who has received wide acclaim for her leadership of MassBio, the world's largest biopharma membership organization,

where she drives the strategy to grow the industry and support member companies as CEO and president.

To better serve the entire life cycle of biopharma companies, Kendalle has expanded MassBio's innovation offerings to include partnering and investor events, an entrepreneurial accelerator, and a network for founders and chief executives. As part of MassBio's commitment to realizing a more diverse and equitable life sciences industry, Kendalle was the driving force behind the organization's launch of the non-profit Bioversity and the opening of its first workforce training center in Dorchester where graduates are prepared for rewarding entry-level careers at local life sciences companies. Kendalle has been an outspoken advocate for the industry in policy debates about state government support for the expansion of the life sciences in Massachusetts, the federal government's intervention into biopharma innovation, and efforts to improve the affordability and accessibility of life-changing medicines, just to name a few.

Kendalle has earned numerous accolades for her leadership, including top recognitions from *Boston Magazine* and the *Boston Business Journal*, and serves on the American Cancer Society Board, where she is Chair for the Eastern New England region, among others.



Jenny Riegel

Deputy Director, Policy | U.S. Securities and Exchange Commission

Jenny joined the U.S. Securities and Exchange Commission's Office of the Advocate for Small Business Capital Formation in July 2019, where she leads the

legal and policy team on regulatory matters, rulemaking commentary, and capital raising issues both internally and externally. Prior to joining the Office, Jenny worked in the Division of Corporation Finance's Office of Small Business Policy, as Senior Special Counsel to the Director

of the Division, and before that in disclosure operations for the Division. Prior to joining the SEC in 2007, Jenny worked in Silicon Valley at the law firm Cooley LLP, where she advised companies on late-stage financings, initial public offerings, and other registered offerings.



John Stanford

Partner & CEO | Novel Strategies

John Stanford is Partner and CEO at Novel Strategies, a Washington, D.C.-based government affairs and strategic advisory firm. He leads the firm's healthcare, biotechnology, and

innovation policy practice, advising companies, investors, and trade associations on navigating Congress, federal agencies, and the political dynamics shaping medical innovation and capital formation.

John is a trusted policy insider on drug development, regulatory strategy, and intellectual-property protection, with deep experience translating complex science and investment issues into actionable federal policy outcomes. His work spans drug pricing, FDA regulation, IP policy, and global competitiveness for the U.S. life-sciences sector.

He is a frequent contributor to *The Wall Street Journal*, CNBC, STAT, Bloomberg, and *The Washington Post*, and hosts the Making Medicine podcast, where he interviews biotech CEOs, investors, and policymakers on the future of medicine and innovation policy.

Presenting Companies

Advanced Biologics & Protein Therapeutics



Headquarters: Oslo, Norway

Founding Year: 2024

Overview: Calluna Pharma is a clinical-stage biotech developing novel antibody therapeutics for a range of fibrotic and inflammatory diseases. The company targets upstream innate immune amplifiers, with lead candidate CAL101 directed against S100A4 and a second program targeting oxidized phospholipids.

Funding Stage: Series A

Developmental Stage: Phase 2



Headquarters: Boston, MA, USA

Founding Year: 2023

Overview: Consano Bio is a clinical-stage biotechnology company advancing a novel therapeutic designed to address serious pain conditions where conventional therapies are limited or ineffective.

Funding Stage: Series A

Developmental Stage: Phase 1/2



Headquarters: Boston, MA, USA

Founding Year: 2026

Overview: Harmonia Therapeutics engineers logic-gated ADCs that sense and respond to their extracellular and intracellular environment to activate exclusively in cancer cells, dramatically improving safety and efficacy for treatment-resistant cancers.

Funding Stage: Pre-Seed

Developmental Stage: Discovery

Drive: DRIVE S26 Biotech Cohort



Headquarters: Cambridge, MA, USA

Founding Year: 2026

Overview: Hiba Therapeutics is an Immuno-Oncology company, our TROIKA platform is an AI-enabled programmable, AND-gated, modular biologics discovery platform. Using TROIKA, we have created a novel, lung cancer targeted therapeutics, which activates tumor-residing potent antiviral T cells to kill solid cancers, delivering best-in-class efficacy with strong safety profile.

Funding Stage: Pre-Seed

Developmental Stage: Pre-Clinical



Headquarters: Boston, MA, USA

Founding Year: 2020

Overview: IMMEDIATE Therapeutics is developing IMT-358, a first-in-class metabolic stabilization therapy designed to reduce irreversible ischemic injury before reperfusion. Administered in the prehospital and early hospital setting, IMT-358 has demonstrated significant reductions in infarct size, cardiac arrest, and mortality in a randomized clinical trial and is being advanced as a platform for cardioprotection and organ preservation across acute coronary syndromes, high-risk surgery, stroke, and other ischemic conditions. IMMEDIATE Therapeutics is a 2020 MassConnect alum.

Funding Stage: Series B

Developmental Stage: Phase 3



Headquarters: Modi'in, Israel

Founding Year: 2017

Overview: KAHR Bio is a phase 2 immuno-oncology company turning cancer's own defenses against it: its lead asset converts a mechanism tumors use to evade immune attack, into a signal that recruits and activates cancer-killing T-cells at the tumor site, resulting in 17.5 months median overall survival in a phase 2a study in late-line metastatic MSS colorectal cancer, as compared to historical controls of 6.4–10.8 months.

Funding Stage: Series B

Developmental Stage: Phase 2



Headquarters: Woburn, MA, USA

Founding Year: 2024

Overview: Laurel Biotherapeutics is a preclinical biotechnology company developing first-in-class VHH-based biologics for cardiorenal diseases. The company is advancing a pipeline of therapeutics spanning cardiovascular and renal disease, metabolism, and cardioimmunology, with an initial focus on acute decompensated heart failure (ADHF) with renal dysfunction.

Funding Stage: Pre-Seed

Developmental Stage: Discovery

Drive: DRIVE S26 Biotech Cohort



Othelium Therapeutics

Headquarters: Cambridge, MA, USA

Founding Year: 2026

Overview: Othelium Therapeutics is developing ApoM-Fc to restore endothelial function to treat vascular aging in chronic kidney disease and heart failure.

Funding Stage: Pre-Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE S26 Biotech Cohort

Presenting Companies



Headquarters: Cambridge, MA, USA

Overview: Overture Therapeutics is developing antibody medicines for obesity and cardiometabolic disease. Its lead program, OVT-109, is a potential first-antibody-in-class, selective, long-acting antagonist of an emerging GPCR whose loss-of-function protects against obesity, designed to recapitulate its metabolic benefits, including reduced weight and adiposity. Overture is advancing OVT-109 toward nonhuman primate studies in Q4 2026.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE F26 Biotech Cohort



Headquarters: Watertown, MA USA

Founding Year: 2022

Overview: PathCision Medicine is developing InfilPath™, a tissue-penetrating biologics platform designed to deliver cancer drugs deep into solid tumors, starting with colorectal and pancreatic cancers.

Funding Stage: Seed

Developmental Stage: Pre-Clinical



Headquarters: Cambridge, MA, USA

Founding Year: 2020

Overview: Valink Therapeutics discovers and develops complex biologics with standard-of-care potential. A pre-clinical biotechnology company, Valink's lead asset is truly differentiated bsADC for colorectal cancer as part of a rich pipeline of internal programmes across indications and modalities.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

AI for Drug Discovery & Development



Headquarters: Cambridge, MA, USA

Founding Year: 2024

Overview: Absentia Labs is an AI biotechnology company building foundation models of human biology that predict drug safety and efficacy, helping pharmaceutical companies make better development decisions, reduce reliance on animal testing, and accelerate the delivery of safer medicines.

Funding Stage: Seed

Developmental Stage: Full product/offering ready for market



Headquarters: Belfast, United Kingdom

Founding Year: 2022

Overview: AMPLY's thesis is that drug discovery ignores most of human biology – it focuses on 2% of the genome that codes for proteins and ignores the other 98%, where a lot of disease regulation lives. AMPLY discovers new drug targets in the dark genome. Unlocking the dark genome will open-up 98% of the real estate in human biology and will transform how we deliver partner-ready drug discovery programmes. Partner with AMPLY to rapidly discover druggable non-coding targets, novel potent peptides, and siRNA, or license from among our portfolio of anti-infectives and anti-cancer agents.

Funding Stage: Seed

Developmental Stage: Discovery



Headquarters: Boston, MA, USA

Founding Year: 2025

Overview: AI/ML-enabled breakthrough in direct targeting of toxic lipids for neurodegeneration.

Funding Stage: Pre-Seed

Developmental Stage: Pre-Clinical



Headquarters: Montevideo, Uruguay

Founding Year: 2024

Overview: GUSKA is an AI-powered biotech developing programmable RNA-based oncolytic virotherapies for aggressive solid tumors. By combining synthetic virology, proprietary viral attenuation technologies, and generative AI, GUSKA designs therapeutic candidates intended to selectively destroy cancer cells, release neoantigens and inflammatory signals, and activate anti-tumor immunity. GUSKA is advancing a pipeline focused on hard-to-treat cancers such as glioblastoma and pancreatic cancer.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE F26 Techbio Cohort



Headquarters: Boston, MA, USA

Founding Year: 2025

Overview: Marendis Therapeutics is a TechBio company that predicts cancer's escape routes and develops first-in-class precision therapies to block them preemptively. Our signaling intelligence platform, EVOLVE, combines phosphoproteomics-driven multiomics with AI to uncover adaptive signaling mechanisms, predict drug resistance, and reveal novel therapeutic vulnerabilities.

Funding Stage: Pre-Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE F26 Techbio Cohort

Presenting Companies

neoclease

Headquarters: Boston, MA, USA

Founding Year: 2023

Overview: Neoclease is a Boston techbio company using generative AI to design compact gene editors, one target at a time. Instead of adapting the same few natural CRISPR proteins to every gene, we design a custom editor for each therapeutic target, small enough to deliver in a single AAV and able to reach sites conventional editors can't. Our lead program targets hyperactive LRRK2 in Parkinson's disease, with additional editors advancing in oncology.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE F26 Techbio Cohort

Profluent

Headquarters: Emeryville, CA, USA

Founding Year: 2022

Overview: Profluent uses proprietary sequence-based LLMs to help partners with de novo protein design and optimization.

Funding Stage: Other

Developmental Stage: Pre-Clinical

urieGen

Headquarters: Nijmegen, Netherlands

Founding Year: 2022

Overview: UrieGen is a techbio company building a "Google Maps for cells" to de-risk and accelerate drug discovery. We create AI-powered virtual cell models to understand how cells respond to treatment, behave in disease, and transition between states. What sets us apart is our integrated approach: proprietary single-cell multi-omics technologies, high-quality in-house datasets, and causal AI models spanning RNA, proteins, phosphoproteins, and epigenetics. Combined with a lab-in-the-loop approach, we map how soft and hard perturbations reshape cellular systems.

Funding Stage: Seed

Developmental Stage: Commercialization

Drive: DRIVE F26 Techbio Cohort

ScriptBio AI

Headquarters: Cambridge, MA, USA

Founding Year: 2025

Overview: ScriptBio AI is a causal-AI target-discovery company for diseases of aging. ScriptBio's platform trains a foundation model to separate healthy aging from disease, then applies causal inference to pinpoint the genes that drive tissue degeneration, not just the ones that correlate with it. In knee osteoarthritis, our lead indication, the engine produced a ranked shortlist of candidate drivers that is significantly enriched for genetically validated disease genes and led by novel targets rather than familiar ones. Our lead program is an engineered cell therapy that senses inflammation in the joint and releases a protective payload on demand.

Funding Stage: Pre-Seed

Developmental Stage: Discovery

Drive: DRIVE F26 Techbio Cohort

Switchback Therapeutics

Headquarters: San Carlos, CA, USA

Founding Year: 2025

Overview: Combinatorial biology at scale: AI-accelerated development of novel bispecific antibodies for autoimmune and inflammatory diseases.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

UNRAVEL BIOSCIENCES

Headquarters: Medford, MA, USA

Founding Year: 2021

Overview: Unravel Biosciences is a clinical-stage therapeutics and personalized medicine company, integrating AI systems biology computation with rapid clinical validation of discovered targets. Unravel leverages its proprietary BioNAV™ platform combining target and drug discovery, patient stratification, and clinical validation to find treatments for complex diseases using a systematic, data-driven approach called Predictable Medicine™. It is scaling up its personalized medicine product via concierge care practices and direct to patient marketing.

Funding Stage: Seed

Developmental Stage: Phase 1

Diagnostics and Biomarkers

AGED DIAGNOSTICS

Headquarters: Bethesda, MD, USA

Founding Year: 2020

Overview: The first accurate blood test to diagnose MASH (fatty liver disease) and liver fibrosis across the full spectrum of disease.

Funding Stage: Series A

Developmental Stage: Phase 2/3

CELLENS

Headquarters: Boston, MA, USA

Founding Year: 2020

Overview: Cellens is pioneering Uro CytoSense™, a first-of-its-kind, non-invasive urine-based bladder cancer recurrence test that combines atomic force microscopy and proprietary machine learning to generate objective biophysical biomarkers and reduce reliance on repeated cystoscopy.

Funding Stage: Seed

Developmental Stage: Clinical

Presenting Companies



Headquarters: Branford, CT, USA

Founding Year: 2022

Overview: CellsBin® is a technology-bio company building advanced nanophotonic and AI platforms that detect, characterize and isolate ultra rare cells, down to 1 in 1,000,000, in the human body to enable early cell-based diagnostics and advance cell and gene therapies.

Funding Stage: Series A

Developmental Stage: Marketed product/offering



Headquarters: Boston, MA, USA

Founding Year: 2022

Overview: Diagnosing the undiagnosed with hypothesis free infectious disease testing.

Funding Stage: Series B

Developmental Stage: Commercialization



Headquarters: Melbourne, (VIC), Australia

Founding Year: 2020

Overview: Diag-Nose is building the molecular intelligence layer for precision respiratory medicine. Our platform combines proprietary nasal liquid biopsies with multi-omics and AI to generate and interpret molecular data directly from the airway. This enables biomarker discovery, patient stratification and treatment-response prediction, helping pharmaceutical companies develop better targeted therapies and identify the patients most likely to benefit, with a current focus on anti-Th2 biologics.

Funding Stage: Seed

Developmental Stage: Product/offering in development



Headquarters: Glasgow, United Kingdom

Founding Year: 2019

Overview: Dxcover is a commercial-stage diagnostics company using artificial intelligence and infrared spectroscopy to develop scalable liquid biopsies that enable earlier cancer detection and improved patient outcomes.

Funding Stage: Series A

Developmental Stage: Full product/offering ready for market

Drive: DRIVE S26 Diagnostics & Biomarkers Cohort



Headquarters: Boston, MA USA

Founding Year: 2020

Overview: General Prognostics is developing CardiID, a software-only, device-agnostic digital biomarker platform that analyzes passive physiology from consumer wearables to help clinicians identify early signs of worsening heart failure, confirm risk with biomarkers such as NT-proBNP, and intervene earlier to reduce preventable hospitalizations.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE S26 Diagnostics & Biomarkers Cohort



Headquarters: Cambridge, MA, USA

Founding Year: 2019

Overview: Nanopath is a first-in-class molecular diagnostics company working to improve women's health through rapid, laboratory-quality testing at the point of care.

Funding Stage: Series A

Developmental Stage: Pre-Clinical



Headquarters: Cambridge, MA, USA

Founding Year: 2025

Overview: NeuroSkye Therapeutics is building a human CNS delivery intelligence platform around scalable, patient-relevant 3D blood-brain barrier and brain tumor barrier models. The platform generates quantitative human transport data, including penetration, tissue retention, and cell-specific delivery, to help CNS drug developers prioritize therapeutics before costly animal studies or clinical development and build increasingly predictive AI-driven models of brain delivery.

Funding Stage: Pre-Seed

Developmental Stage: Full product/offering ready for market

Drive: DRIVE S26 Diagnostics & Biomarkers Cohort



Headquarters: Cambridge, MA, USA

Founding Year: 2024

Overview: Nine Diagnostics is redefining how treatment effectiveness is determined. Rather than waiting months for imaging or clinical progression, our AI-enabled blood tests detect rapid biological response from a simple blood draw. This enables faster clinical decisions, improves patient stratification, and supports more efficient drug development. We are building the foundation for a more responsive, feedback-driven model of precision medicine.

Funding Stage: Pre-Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE S26 Diagnostics & Biomarkers Cohort



Headquarters: Surry Hills, NSW, Australia

Founding Year: 2021

Overview: PolygenRx develops gene network-based biomarkers that improve patient stratification for drug development and clinical care, enabling more effective precision therapeutics across common diseases.

Funding Stage: Seed

Developmental Stage: Product/offering in development

Presenting Companies

Engineered Molecular Medicines



Headquarters: Jerusalem, Israel

Overview: BDUK-Tx develops a groundbreaking next generation loco-regional therapy for the \$11B global fast-growing liver cancer market, a disease with low-efficacy and intolerable therapy.

Our product, a novel combination of 3 clinically known components, is superior to current therapies with a de-risked profile. BDUK leadership is supported by world leading medical, scientific and business experts. BDUK is raising \$4M to reach our 1st significant valuation inflection point.

Funding Stage: Pre-seed

Developmental Stage: Pre-Clinical

Drive: DRIVE F26 Biotech Cohort



Headquarters: Newton, MA, USA

Founding Year: 2015

Overview: General Oncology is a biopharmaceutical company whose first-in-class investigational treatment GO-4 for stage IV pancreatic cancer significantly outperforms daraxonrasib in vitro and demonstrated a promising signal of efficacy in a phase 1 trial, with 2 of 4 evaluable patients at higher doses remaining free of disease at 54 and 37 months.

Funding Stage: Series A

Developmental Stage: Phase 1



Headquarters: Phoenix, AZ, USA

Overview: Illuminos Therapeutics is pioneering novel small molecule pipeline programs to address profound unmet medical needs across both central nervous system disorders and metabolic disease. Our lead clinical candidate targets Dyrk1a and its critical downstream pathways to deliver transformative, disease-modifying outcomes across four high-value indications: Alzheimer's disease, related tauopathies, Down syndrome, and Type 1 diabetes.

Funding Stage: Seed

Developmental Stage: IND-Enabling

Drive: DRIVE F26 Biotech Cohort



Headquarters: Watertown, MA, USA

Founding Year: 2020

Overview: Oral pill for autism, obesity, and dementia that targets a novel shared mechanism.

Funding Stage: Seed

Developmental Stage: IND-Enabling



Headquarters: Toronto, Ontario, Canada

Founding Year: 2023

Overview: Noa Therapeutics is a preclinical biotechnology company developing the first biased Aryl Hydrocarbon Receptor (AhR) small molecule therapeutics, unlocking a validated but historically undruggable immune target to fully unlock its vast therapeutic utility across chronic inflammatory barrier diseases without compromising safety.

Funding Stage: Seed

Developmental Stage: Pre-Clinical



Headquarters: Allston, MA, USA

Founding Year: 2021

Overview: We are developing oral non-immunosuppressive small molecules to address the root cause of inflammatory disease.

Funding Stage: Seed

Developmental Stage: Pre-Clinical



Headquarters: Baltimore, MD, USA

Founding Year: 2016

Overview: Rapafusyn discovers and develops novel non-degrading molecular glues (RapaGlues) for hard to drug targets and for targets where selectivity against homologous proteins has been historically challenging. Our platform consists of 12+ billion molecular glues in DEL format, which is the largest library of its kind in the world.

Funding Stage: Series B

Developmental Stage: Pre-Clinical



Headquarters: Delaware, USA

Founding Year: 2022

Overview: Relevium Medical is developing RM-010, a new chemical entity that, for the first time ever, unlocks the full clinical potential of capsaicin — delivering superior, longer-lasting non-opioid pain relief for knee osteoarthritis without the burning sensation that has limited this class of drugs for decades, starting with a \$21B+ U.S. market and expanding across a \$75B+ multi-indication pain platform.

Funding Stage: Seed

Developmental Stage: IND-Enabling

Presenting Companies



Headquarters: Belfast, United Kingdom

Founding Year: 2024

Overview: SignaCor is a clinical stage, cardiology drug development company, developing a first-in-class therapeutic approach to treat the underlying causes of hypertrophic cardiomyopathy.

Funding Stage: Series A

Developmental Stage: Phase 2



Headquarters: Boston, MA, USA

Founding Year: 2025

Overview: Skeletalis is a Boston-based therapeutics company developing a new class of bone medicines that confine a drug's activity to the skeleton and switch it on only where bone is being lost, designed to treat osteoporosis and other degenerative bone diseases by correcting disease-driven bone loss while sparing the body's own bone remodeling.

Funding Stage: Seed

Developmental Stage: Pre-Clinical



Headquarters: Cambridge, MA, USA

Founding Year: 2020

Overview: Unison Medicines develops first-in-class oral small molecules which treat bacterial infection without damaging the gut microbiome.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

Next-Generation Genetic Technologies



Amaryllis Therapeutics

Headquarters: Cambridge, MA, USA

Founding Year: 2024

Overview: Amaryllis Therapeutics is a CNS biotech advancing amarricin, a proprietary cyclic peptide shuttle identified through high-throughput in silico and in vivo screening, which carries siRNA, antibodies, and other therapeutic payloads across the blood-brain barrier from a simple subcutaneous (SC) injection, demonstrated by ~40% knockdown of alpha-synuclein protein in mouse brain after a single SC dose of an amarricin-siRNA conjugate, opening a path to self-administered, chronically dosed medicines for Alzheimer's, Parkinson's, and other neurological diseases.

Funding Stage: Seed

Developmental Stage: IND-Enabling



Headquarters: Columbus, OH, USA

Founding Year: 2021

Overview: Armatus Bio is a late preclinical-stage company advancing vectorized RNAi technology to address rare neuromuscular diseases, with lead programs focused on FSHD and CMT1A, both relatively common orphan indications with no FDA-approved medicines today.

Funding Stage: Seed

Developmental Stage: IND-Enabling



Headquarters: Waltham, MA, USA

Founding Year: 2018

Overview: FluidForm Bio is developing a 3D bioprinting platform for manufacturing vascularized living tissues, initially to enable a retrievable cell therapy for Type 1 diabetes and ultimately a broad range of regenerative medicine applications.

Funding Stage: Series A

Developmental Stage: Pre-Clinical



Headquarters: Cambridge, MA, USA

Founding Year: 2021

Overview: Gensaic is a multifunctional-RNA medicines company developing extrahepatic dual-siRNA therapies for Obesity, metabolic disease and aging.

Funding Stage: Series A

Developmental Stage: Pre-Clinical



Headquarters: Cambridge, MA, USA

Founding Year: 2024

Overview: GT Biosciences is a TechBio company focused on discovering and engineering targeting ligands for next-generation genetic medicines. As an initial application, we are developing ligand-directed delivery systems designed to transport genetic medicines and gene editors across the blood-brain barrier and selectively reach specific cell types in the brain. By combining ligand discovery, nanoparticle engineering, and AI-guided in vivo screening, we aim to build a scalable platform for cell-type-specific delivery in the CNS and, ultimately, other difficult-to-reach tissues.

Funding Stage: Seed

Developmental Stage: Discovery

Drive: DRIVE S26 Diagnostics & Biomarkers Cohort

Presenting Companies



Headquarters: London, Ontario, Canada

Founding Year: 2024

Overview: i-RNA Corporation is developing first-in-class RNA therapeutics for retinal diseases, leveraging a novel lncRNA target and non-invasive topical delivery to transform the treatment of diabetic retinopathy and other vision-threatening disorders.

Funding Stage: Pre-Seed

Developmental Stage: Pre-Clinical



Headquarters: Columbus, OH, USA

Founding Year: 2024

Overview: RNA NanoBiotics is developing engineered intracellular combination cancer therapeutics that use programmable RNA nanoparticles to precisely target tumors and deliver three synergistic therapeutic payloads with programmed staggered intracellular release from a single molecular construct.

Funding Stage: Seed

Developmental Stage: Pre-Clinical



Syndeo Life

Headquarters: Baltimore, MD, USA

Founding Year: 2025

Overview: Syndeo Life is Johns Hopkins spinout biotech developing gene therapies and biomarkers for neurodegenerative diseases driven by TDP-43 dysfunction. Its lead program, AAV9-CTR, is designed to restore TDP-43 splicing repression across the transcriptome in amyotrophic lateral sclerosis (ALS). Syndeo is advancing a proprietary fluid biomarker platform to support patient selection and target engagement, with potential expansion into FTD and Alzheimer's disease.

Funding Stage: Seed

Developmental Stage: IND-Enabling

Drive: DRIVE F26 Biotech Cohort



Headquarters: Boston, MA, USA

Founding Year: 2017

Overview: Tvard Biosciences is pioneering a gene-agnostic suppressor tRNA platform designed to restore full-length protein production by correcting mutations that lead to premature stop codons, an innovative and universal therapeutic modality with the potential to address thousands of diseases that share this common pathogenic genetic mechanism.

Funding Stage: Series A

Developmental Stage: Pre-Clinical



Headquarters: Charleston, SC, USA

Founding Year: 2025

Overview: Theripio Innovations is advancing transformative therapies for rare pediatric neurological disorders caused by single-gene mutations. Our lead program targets MEF2C Haploinsufficiency Syndrome, a lifelong disability that severely impacts a child's ability to move, communicate, and learn. Our unique approach restores critical protein function directly within affected cells, allowing for treatments that are more precise, less invasive, and faster to reach patients than traditional strategies.

Funding Stage: Pre-seed

Developmental Stage: Pre-Clinical

Drive: DRIVE S26 Biotech Cohort



Headquarters: Miami, FL, USA

Founding Year: 2024

Overview: Tinker Therapeutics has pioneered the novel FORGE™ multimeric oligonucleotides platform, which delivers best-in-class multi-targeting RNA therapeutics (ASOs/siRNAs) for polygenic neurodegenerative disorders, with leads for Alzheimer's Disease and Pain.

Funding Stage: Seed

Developmental Stage: Pre-Clinical

Drive: DRIVE S26 Biotech Cohort

ENDPOINTSNEWS
THE BIOPHARMA WORLD IS HERE

The daily read for people building and funding biotech

Main Edition brings you the day's biopharma news and analysis, from a newsroom that breaks it first. **Free** in your inbox every business day at 11:30 a.m. ET.

 endpoints.news



Get Main Edition

About MassBio Programs & Initiatives

MassBio provides a robust roster of programs and offerings exclusive to its members. Visit massbio.org for more information.

MassBioEdge

MassBio's savings and rewards program aggregates members' purchasing power to offer competitive discounts, favorable terms and conditions, and personalized customer service on critical products and services.

MassBioHub

MassBio's conference and business center is a versatile space designed to meet all your business needs, serving as a venue for innovation and collaboration.

Drive Life Sciences

MassBio's startup accelerator advances breakthrough science and provides opportunities to innovators by connecting them with business curriculum, mentorship, industry connections, and equity-free prizes.

Policy & Advocacy

MassBio's dynamic policy and government affairs team cultivates enduring relationships, gives the industry a voice in the halls of government, and possesses deep experience and networks to promote policies that foster a robust biotechnology ecosystem, and patient access to cutting-edge therapies, in Massachusetts.



Professional Development

Through our events, employees receive professional development and networking opportunities on industry topics, expert best practices, the latest industry news, and connections, and bring that insight and training back to your company.

Partnering Opportunities

Harnessing MassBio's expansive network and deep connections in the life sciences industry, MassBio's partnering events help to identify emerging companies, technologies, and assets to build partnerships and external innovation with leading biopharmaceutical companies and investors.

For more information and to reserve your event sponsorship, please contact sponsorships@massbio.org.

Not yet a
MassBio member?

Visit massbio.org/become-a-member



Learn More

Thank You to Our Drive Sponsors

MASSBIO 2026 DRIVE SPONSORS

PREMIER SPONSORS



SUPPORTING SPONSOR



CURRICULUM SPONSORS



SCBIO 2026 DRIVE SPONSORS

PREMIER SPONSORS



CURRICULUM SPONSORS



Thank You to Our Align Summit Sponsors

GOLD



SUSTAINING



SILVER



COPPER

